{"id":"NCT02798471","sponsor":"Daiichi Sankyo","briefTitle":"Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)","officialTitle":"A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-03-27","primaryCompletion":"2022-05-24","completion":"2022-05-24","firstPosted":"2016-06-14","resultsPosted":"2023-03-06","lastUpdate":"2025-02-28"},"enrollment":290,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Venous Thromboembolism (VTE)","Pulmonary Embolism","Deep Vein Thrombosis (DVT)"],"interventions":[{"type":"DRUG","name":"Edoxaban","otherNames":[]},{"type":"DRUG","name":"Standard of Care","otherNames":["Warfarin/heparin","Enoxaparin","Fondaparinux"]}],"arms":[{"label":"Edoxaban","type":"EXPERIMENTAL"},{"label":"Standard of Care","type":"EXPERIMENTAL"}],"summary":"This is an event driven Phase 3, prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study in subjects with confirmed VTE. This study is designed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of edoxaban and to compare the efficacy and safety of edoxaban against standard of care in pediatric subjects with confirmed VTE.","primaryOutcome":{"measure":"Number of Participants With Symptomatic Recurrent Venous Thromboembolism During the Main Treatment Period Following Edoxaban or Standard of Care Treatment (Adjudicated Composite)","timeFrame":"Randomization to Month 3","effectByArm":[{"arm":"Edoxaban","deltaMin":5,"sd":null},{"arm":"Standard of Care","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9694"}]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":140,"countries":["United States","Argentina","Brazil","Bulgaria","Canada","Chile","Croatia","Czechia","Denmark","El Salvador","France","Germany","Guatemala","Hungary","India","Israel","Kenya","Lebanon","Malaysia","Netherlands","Norway","Panama","Portugal","Romania","Russia","Serbia","Singapore","Slovenia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["23991658"],"seeAlso":["http://www.nejm.org/doi/full/10.1056/NEJMoa1306638"]},"adverseEventsSummary":{"seriousAny":{"events":44,"n":145},"commonTop":["Headache","Vomiting","Pyrexia","Epistaxis","Upper respiratory tract infection"]}}